Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBIT (2016 - 2025)

Historic EBIT for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's EBIT rose 4043.55% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.8 million, marking a year-over-year increase of 2540.41%. This contributed to the annual value of -$46.9 million for FY2024, which is 1621.49% up from last year.
  • Per Theravance Biopharma's latest filing, its EBIT stood at -$6.5 million for Q3 2025, which was up 4043.55% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EBIT registered a high of -$2.7 million during Q2 2025, and its lowest value of -$83.9 million during Q1 2021.
  • Its 5-year average for EBIT is -$25.1 million, with a median of -$15.7 million in 2024.
  • In the last 5 years, Theravance Biopharma's EBIT soared by 8294.51% in 2022 and then crashed by 4743.59% in 2024.
  • Theravance Biopharma's EBIT (Quarter) stood at -$56.2 million in 2021, then skyrocketed by 68.96% to -$17.4 million in 2022, then surged by 64.2% to -$6.2 million in 2023, then plummeted by 47.44% to -$9.2 million in 2024, then rose by 29.84% to -$6.5 million in 2025.
  • Its EBIT was -$6.5 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$14.4 million in Q1 2025.